Home / Resources / Dealmaking Q1 Review

Dealmaking Q1 Review

eBook
商業化支援サービス
Stock chart displaying market trends and fluctuations.

Ahead of BIO-Europe, our In Vivo journalists have explored some of the biggest deals and trends that have already shaped the start of 2024. Read on as we discuss what big pharma is looking for in strategic partners, who really were the biggest deal makers of 2023, what private equity and VC have been investing in, and why new company creation has slowed down.

Related products
KOL thought leader interview
In Vivo
ライフサイエンスの意思決定者のためのインタビュー、分析、重要な洞察
Analyst visualizing the drug development process on screen
Biomedtracker
医薬品開発パイプラインのリアルタイム追跡と分析
Health Beauty and Wellness
HBW Insight
健康、美容、ウェルネスセクターのニュースと洞察のための単一の情報源

Related resources

PDF preview of the Biomedtracker Meddevicetracker Q4 2023 Outlook Report.
FEB 01, 2024
Report
商業化支援サービス

Biomedtracker / Meddevicetracker Q4 2023 Outlook Report

Discover anticipated Q4 2023 catalysts: 32 drugs, devices, diagnostics, and deals. For each, assess Phase/PDUFA success likelihood and overall Likelihood of Approval (LOA) based on phase, drug class, and disease.

Webinar announcement featuring the panelists.
Webinar
商業化支援サービス

Deal-Making: Scouting for Expertise Webinar with Ipsen

Catch up with Ipsen and Citeline to hear the latest for deal-making, cutting through the noise to find the right deal and securing competitive alliances.